MX361874B - Anticuerpos frente a los ligandos del receptor b1 de bradicinina. - Google Patents

Anticuerpos frente a los ligandos del receptor b1 de bradicinina.

Info

Publication number
MX361874B
MX361874B MX2014011688A MX2014011688A MX361874B MX 361874 B MX361874 B MX 361874B MX 2014011688 A MX2014011688 A MX 2014011688A MX 2014011688 A MX2014011688 A MX 2014011688A MX 361874 B MX361874 B MX 361874B
Authority
MX
Mexico
Prior art keywords
kallidin
antibodies
des
arg10
disclosure
Prior art date
Application number
MX2014011688A
Other languages
English (en)
Other versions
MX2014011688A (es
Inventor
Chen Xin
Baurin Nicolas
Li Han
Kominos Dorothea
Zhang Jie
Pritsker Alla
Davidson Matthew
Subramanian Govindan
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361874(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2014011688A publication Critical patent/MX2014011688A/es
Publication of MX361874B publication Critical patent/MX361874B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen específicamente a calidina o des-Arg10-calidina. La descripción también proporciona composiciones farmacéuticas, así como ácidos nucleicos que codifican anticuerpos anti-calidina y anti des-Arg10-calidina, vectores de expresión recombinantes y células huésped para producir tales anticuerpos, o fragmentos de los mismos. Métodos para usar los anticuerpos de la descripción, para modular la actividad de calidina o des-Arg10-calidina o para detectar calidina y des-Arg10-calidina o, ya sea in vitro o in vivo, son también proporcionados por la descripción. La descripción proporciona además métodos de producción de anticuerpos que se unen específicamente a des-Arg9-bradicinina y péptido tipo des-Arg10-calidina.
MX2014011688A 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina. MX361874B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Publications (2)

Publication Number Publication Date
MX2014011688A MX2014011688A (es) 2015-01-22
MX361874B true MX361874B (es) 2018-12-18

Family

ID=49261064

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014011688A MX361874B (es) 2012-03-28 2013-03-15 Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
MX2018015914A MX2018015914A (es) 2012-03-28 2014-09-26 Anticuerpos frente a los ligandos del receptor b1 de bradicinina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018015914A MX2018015914A (es) 2012-03-28 2014-09-26 Anticuerpos frente a los ligandos del receptor b1 de bradicinina.

Country Status (39)

Country Link
US (5) US9376494B2 (es)
EP (2) EP3246339B1 (es)
JP (4) JP6779012B2 (es)
KR (4) KR102166083B1 (es)
CN (2) CN113773385A (es)
AR (1) AR090352A1 (es)
AU (2) AU2013240242B2 (es)
BR (1) BR112014024282A2 (es)
CA (1) CA2868353C (es)
CL (2) CL2014002590A1 (es)
CO (1) CO7111293A2 (es)
CR (1) CR20140440A (es)
CY (1) CY1121466T1 (es)
DK (2) DK3246339T3 (es)
DO (1) DOP2014000199A (es)
EA (1) EA201491784A1 (es)
ES (1) ES2673869T3 (es)
GT (1) GT201400192A (es)
HK (1) HK1206754A1 (es)
HR (1) HRP20180928T1 (es)
HU (1) HUE037720T2 (es)
IL (1) IL234830B (es)
LT (1) LT2831113T (es)
MA (1) MA37407B1 (es)
MX (2) MX361874B (es)
MY (2) MY184037A (es)
NZ (1) NZ631543A (es)
PE (1) PE20142170A1 (es)
PH (1) PH12014501970A1 (es)
PL (1) PL2831113T3 (es)
PT (1) PT2831113T (es)
RS (1) RS57413B1 (es)
SG (2) SG11201405162YA (es)
SI (1) SI2831113T1 (es)
TR (1) TR201808486T4 (es)
TW (1) TWI605060B (es)
UA (1) UA117097C2 (es)
UY (1) UY34682A (es)
WO (1) WO2013148296A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361874B (es) * 2012-03-28 2018-12-18 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
NZ743482A (en) 2015-12-15 2023-04-28 Takeda Pharmaceuticals Co Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
HUE060258T2 (hu) 2016-05-02 2023-02-28 Prothena Biosciences Ltd Tau immunterápia
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
IL270375B1 (en) * 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
AU2018266711A1 (en) * 2017-05-08 2019-11-28 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
TW201945026A (zh) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 結合erfe之抗體及使用方法
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP0918872B1 (en) 1996-08-02 2008-02-20 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
KR20080015854A (ko) 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 항원 컨쥬게이트 및 그의 용도
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
AR063840A1 (es) * 2006-11-15 2009-02-25 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso
US20110022149A1 (en) 2007-06-04 2011-01-27 Cox Brian J Methods and devices for treatment of vascular defects
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
CA2698203C (en) 2007-08-29 2018-09-11 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their use
MX2010005022A (es) * 2007-11-07 2010-06-02 Celldex Therapeutics Inc Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
MX361874B (es) * 2012-03-28 2018-12-18 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina.

Also Published As

Publication number Publication date
HRP20180928T1 (hr) 2018-07-27
JP6779012B2 (ja) 2020-11-04
JP2019050822A (ja) 2019-04-04
MX2018015914A (es) 2021-12-08
US10465002B2 (en) 2019-11-05
IL234830B (en) 2018-11-29
BR112014024282A2 (pt) 2017-08-08
US20160368976A1 (en) 2016-12-22
EP2831113B1 (en) 2018-03-14
DK3246339T3 (da) 2020-01-27
JP2021166538A (ja) 2021-10-21
PH12014501970A1 (en) 2014-11-17
WO2013148296A1 (en) 2013-10-03
RS57413B1 (sr) 2018-09-28
KR20190121861A (ko) 2019-10-28
PE20142170A1 (es) 2015-01-07
TR201808486T4 (tr) 2018-07-23
HUE037720T2 (hu) 2018-09-28
MY166157A (en) 2018-06-06
MA37407B1 (fr) 2018-03-30
CL2014002590A1 (es) 2015-01-16
KR102367723B1 (ko) 2022-02-28
PT2831113T (pt) 2018-06-20
JP2015513903A (ja) 2015-05-18
EA201491784A1 (ru) 2015-02-27
KR20220031728A (ko) 2022-03-11
MX2014011688A (es) 2015-01-22
US20200115441A1 (en) 2020-04-16
UA117097C2 (uk) 2018-06-25
CR20140440A (es) 2014-11-17
US20150050270A1 (en) 2015-02-19
KR20200121370A (ko) 2020-10-23
MA37407A1 (fr) 2016-05-31
TW201343671A (zh) 2013-11-01
AU2013240242B2 (en) 2018-02-08
UY34682A (es) 2013-10-31
SG11201405162YA (en) 2014-09-26
CN113773385A (zh) 2021-12-10
CN104334578A (zh) 2015-02-04
DK2831113T3 (en) 2018-06-25
SG10201702396QA (en) 2017-04-27
JP2024038036A (ja) 2024-03-19
PL2831113T3 (pl) 2018-08-31
KR102166083B1 (ko) 2020-10-16
CY1121466T1 (el) 2020-05-29
US20230399388A1 (en) 2023-12-14
HK1206754A1 (en) 2016-01-15
KR102035882B1 (ko) 2019-10-24
EP3246339B1 (en) 2019-10-09
SI2831113T1 (en) 2018-08-31
AU2018203081A1 (en) 2018-05-24
EP3246339A1 (en) 2017-11-22
NZ631543A (en) 2017-03-31
LT2831113T (lt) 2018-06-25
CO7111293A2 (es) 2014-11-10
EP2831113A1 (en) 2015-02-04
US9879079B2 (en) 2018-01-30
ES2673869T3 (es) 2018-06-26
CN104334578B (zh) 2021-10-08
CA2868353C (en) 2023-10-31
JP6912441B2 (ja) 2021-08-04
US9376494B2 (en) 2016-06-28
KR20150002679A (ko) 2015-01-07
GT201400192A (es) 2015-07-29
AU2013240242A1 (en) 2014-10-02
AR090352A1 (es) 2014-11-05
MY184037A (en) 2021-03-17
DOP2014000199A (es) 2014-10-31
TWI605060B (zh) 2017-11-11
CA2868353A1 (en) 2013-10-03
JP7411609B2 (ja) 2024-01-11
US20180222967A1 (en) 2018-08-09
CL2017003039A1 (es) 2018-03-16

Similar Documents

Publication Publication Date Title
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MY162737A (en) 4-1bb binding molecules
ZA201405021B (en) Cx3cr1-binding polypeptides
MX357327B (es) Proteinas de union a antigenos del ligando de cd30 humano.
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
TN2012000167A1 (en) Human il-23 antigen binding proteins
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
IN2014MN01562A (es)
MX366622B (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
MX2015005266A (es) Nuevas variantes del receptor iib de fc gamma.
FI20115328A (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
PH12014502182A1 (en) Methods and compositions for modulating notch activity
ECSP14024494A (es) Anticuerpos frente a los Ligandos del receptor B1 de bradicinina

Legal Events

Date Code Title Description
FG Grant or registration